NCT06256484 2026-03-11A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin LymphomaAtara BiotherapeuticsPhase 1 Terminated1 enrolled